NASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $2.94 0.00 (0.00%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.94 0.00 (-0.17%) As of 08/15/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Taysha Gene Therapies Stock (NASDAQ:TSHA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Taysha Gene Therapies alerts:Sign Up Key Stats Today's Range$2.85▼$2.9950-Day Range$2.31▼$3.0352-Week Range$1.05▼$3.31Volume2.89 million shsAverage Volume2.85 million shsMarket Capitalization$631.10 millionP/E RatioN/ADividend YieldN/APrice Target$8.29Consensus RatingBuy Company Overview Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. Read More Taysha Gene Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreTSHA MarketRank™: Taysha Gene Therapies scored higher than 70% of companies evaluated by MarketBeat, and ranked 308th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -8.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -8.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.50% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Taysha Gene Therapies has recently decreased by 13.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.50% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Taysha Gene Therapies has recently decreased by 13.08%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment0.25 News SentimentTaysha Gene Therapies has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search Interest14 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows15 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,062,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.78% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address TSHA Stock News HeadlinesFY2025 EPS Forecast for Taysha Gene Therapies Cut by Analyst1 hour ago | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $8.00August 15 at 2:51 AM | americanbankingnews.comThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And according to Weiss Ratings analyst Juan Villaverde, a major shift is coming. Juan has nailed every major Bitcoin move since 2012—but right now, he says the biggest upside isn’t in BTC or ETH. It’s in a lesser-known altcoin he believes could become the “third pillar of crypto”… and potentially define America’s first true crypto presidency. | Weiss Ratings (Ad)Taysha Gene Therapies price target raised to $14 from $11 at CanaccordAugust 13 at 12:54 AM | msn.com4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...August 13 at 12:54 AM | benzinga.comTaysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...August 13 at 6:13 AM | finance.yahoo.comTaysha Gene Therapies price target raised to $10 from $9 at ChardanAugust 13 at 2:12 AM | msn.comTaysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028August 13 at 2:12 AM | msn.comSee More Headlines TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $1.73 at the beginning of the year. Since then, TSHA shares have increased by 69.9% and is now trading at $2.94. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its earnings results on Tuesday, August, 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.02. The business earned $1.99 million during the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative trailing twelve-month return on equity of 78.44% and a negative net margin of 1,144.97%. Read the conference call transcript. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Taysha Gene Therapies' top institutional investors include Octagon Capital Advisors LP (5.87%), Jefferies Financial Group Inc. (4.80%), Adage Capital Partners GP L.L.C. (2.25%) and Tybourne Capital Management HK Ltd. (1.91%). Insiders that own company stock include RA Session II, Paul B Manning, Sean P Nolan, Kamran Alam and Sukumar Nagendran. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Taysha Gene Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS). Company Calendar Last Earnings8/12/2025Today8/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSHA CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees180Year Founded2020Price Target and Rating Average Price Target for Taysha Gene Therapies$8.29 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+181.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.30 million Net Margins-1,144.97% Pretax Margin-1,144.97% Return on Equity-78.44% Return on Assets-44.82% Debt Debt-to-Equity Ratio0.17 Current Ratio12.48 Quick Ratio5.35 Sales & Book Value Annual Sales$8.33 million Price / Sales75.76 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book2.53Miscellaneous Outstanding Shares214,660,000Free Float206,548,000Market Cap$631.10 million OptionableOptionable Beta0.98 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TSHA) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.